$AYTU
AYTU BIOPHARMA, INC

2016 Q4 Form 10-Q Financial Statement

#000114420416132071 Filed on November 07, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $794.2K $698.0K $487.4K
YoY Change 69.26% 43.21% 1666.98%
Cost Of Revenue $551.3K $190.0K $37.33K
YoY Change 125.85% 409.04% 16488.89%
Gross Profit $242.9K $510.0K $450.1K
YoY Change 7.89% 13.32% 1545.08%
Gross Profit Margin 30.58% 73.07% 92.34%
Selling, General & Admin $3.642M $5.705M $1.563M
YoY Change 115.81% 264.95% 38.18%
% of Gross Profit 1499.65% 1118.58% 347.33%
Research & Development $263.5K $280.0K $855.9K
YoY Change -79.87% -67.28% -8.34%
% of Gross Profit 108.47% 54.9% 190.17%
Depreciation & Amortization $26.00K $822.2K $129.0K
YoY Change 116.67% 537.09% 424.97%
% of Gross Profit 10.7% 161.21% 28.67%
Operating Expenses $4.993M $5.705M $2.650M
YoY Change 43.34% 115.24% 28.35%
Operating Profit -$4.199M -$5.967M -$2.163M
YoY Change 39.31% 175.84% 3.41%
Interest Expense $388.1K $415.4K $113.3K
YoY Change 61.56% 266.77% 203.61%
% of Operating Profit
Other Income/Expense, Net -$618.5K $242.1K -$113.1K
YoY Change 94.26% -314.02% 203.27%
Pretax Income -$4.820M -$5.720M -$2.276M
YoY Change 44.64% 151.3% 6.91%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.817M -$5.724M -$2.276M
YoY Change 44.56% 151.49% 8.13%
Net Earnings / Revenue -606.57% -820.11% -467.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.454B -$4.674B -$7.662B
COMMON SHARES
Basic Shares Outstanding 10.85M shares 5.071M shares 14.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.500M $4.500M $10.10M
YoY Change -40.91% -55.45%
Cash & Equivalents $5.200M $2.700M $10.07M
Short-Term Investments $1.300M $1.800M
Other Short-Term Assets $700.0K $800.0K $600.0K
YoY Change -22.22% 33.33%
Inventory $439.0K $600.0K $494.1K
Prepaid Expenses $360.5K
Receivables $582.4K $500.0K $167.9K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.158M $6.400M $11.31M
YoY Change -36.27% -43.4%
LONG-TERM ASSETS
Property, Plant & Equipment $292.2K $300.0K $26.37K
YoY Change 192.17% 1037.48%
Goodwill $221.0K $74.00K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $300.0K
YoY Change -33.33% -33.33%
Total Long-Term Assets $13.35M $13.84M $10.05M
YoY Change 15.07% 37.66%
TOTAL ASSETS
Total Short-Term Assets $8.158M $6.400M $11.31M
Total Long-Term Assets $13.35M $13.84M $10.05M
Total Assets $21.51M $20.20M $21.36M
YoY Change -11.86% -5.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $2.500M $1.100M
YoY Change 118.18% 127.27%
Accrued Expenses $500.0K $500.0K $600.0K
YoY Change 0.0% -16.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.000M $8.700M $1.778M
YoY Change 150.0% 389.34% 1677.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $4.800M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $4.100M $4.300M $1.300M
YoY Change 192.86% 230.77%
Total Long-Term Liabilities $4.100M $4.300M $6.100M
YoY Change -34.92% -29.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.000M $8.700M $1.778M
Total Long-Term Liabilities $4.100M $4.300M $6.100M
Total Liabilities $11.10M $13.00M $7.951M
YoY Change 20.65% 63.5% 7850.85%
SHAREHOLDERS EQUITY
Retained Earnings -$20.66M
YoY Change
Common Stock $39.07M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.40M $7.200M $13.41M
YoY Change
Total Liabilities & Shareholders Equity $21.50M $20.20M $21.36M
YoY Change -11.89% -5.43%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$4.817M -$5.724M -$2.276M
YoY Change 44.56% 151.49% 8.13%
Depreciation, Depletion And Amortization $26.00K $822.2K $129.0K
YoY Change 116.67% 537.09% 424.97%
Cash From Operating Activities -$2.840M -$5.330M -$2.160M
YoY Change -17.68% 146.76% 21500.0%
INVESTING ACTIVITIES
Capital Expenditures -$2.040M $4.721K $3.554K
YoY Change 1469.23% 32.84%
Acquisitions
YoY Change
Other Investing Activities -$250.0K -$500.0K
YoY Change -53.7%
Cash From Investing Activities -$2.290M -$500.0K $0.00
YoY Change 246.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $631.5K $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.600M 610.0K 4.880M
YoY Change 52.0% -87.5%
NET CHANGE
Cash From Operating Activities -2.840M -5.330M -2.160M
Cash From Investing Activities -2.290M -500.0K 0.000
Cash From Financing Activities 7.600M 610.0K 4.880M
Net Change In Cash 2.470M -5.220M 2.720M
YoY Change 177.53% -291.91% -27300.0%
FREE CASH FLOW
Cash From Operating Activities -$2.840M -$5.330M -$2.160M
Capital Expenditures -$2.040M $4.721K $3.554K
Free Cash Flow -$800.0K -$5.335M -$2.164M
YoY Change -75.9% 146.57% 21535.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-11379 USD
CY2016Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2016Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
60650 USD
CY2015Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
454638 USD
CY2016Q3 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-75 USD
CY2015Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21428 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-5724390 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2276188 USD
CY2016Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-70609 USD
CY2015Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
128 USD
CY2016Q3 aytu Warrant Derivative Liability Related To Issuance Of Convertible Promissory Notes
WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes
0 USD
CY2015Q3 aytu Warrant Derivative Liability Related To Issuance Of Convertible Promissory Notes
WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes
102931 USD
CY2016Q3 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2016Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5332459 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2157160 USD
CY2016Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-504721 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3554 USD
CY2016Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
607234 USD
CY2015Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4876678 USD
CY2016Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5229946 USD
CY2015Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2715964 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7353061 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10069025 USD
CY2016Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
347013 USD
CY2015Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10872 USD
CY2015Q3 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
298322 USD
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
822161 USD
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
129049 USD
CY2016Q3 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
500000 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-113125 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
242110 USD
CY2015Q3 us-gaap Interest Expense
InterestExpense
113253 USD
CY2016Q3 us-gaap Interest Expense
InterestExpense
415381 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2163063 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5966500 USD
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1563179 USD
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5704750 USD
CY2015Q3 aytu Research And Development Related Party
ResearchAndDevelopmentRelatedParty
47998 USD
CY2016Q3 aytu Research And Development Related Party
ResearchAndDevelopmentRelatedParty
47998 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
2650448 USD
CY2016Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
728100 USD
CY2015Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
CY2016Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
50772 USD
CY2015Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
88625 USD
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
130000 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
112000 USD
CY2016Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
1769000 USD
CY2016Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
1041000 USD
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
20000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
35000 USD
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
18000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
322302 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
441999 shares
CY2016Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2084 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
254131 shares
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.23
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.01
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2016Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
18.12
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.44
CY2016Q3 aytu Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant
71117 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
762217 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.52
CY2016Q3 aytu Unrecognized Share Based Compensation Expenses
UnrecognizedShareBasedCompensationExpenses
1906000 USD
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y5M23D
CY2016Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
13837025 USD
CY2016Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
14222780 USD
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5110591 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5110591 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3741944 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3741944 shares
CY2016Q3 dei Document Type
DocumentType
10-Q
CY2016Q3 dei Amendment Flag
AmendmentFlag
false
CY2016Q3 dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
CY2016Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2016Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q3 dei Entity Registrant Name
EntityRegistrantName
AYTU BIOSCIENCE, INC
CY2016Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001385818
CY2016Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2016 aytu Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P4Y8M16D
CY2016Q3 aytu Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P4Y5M19D
CY2016Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q3 dei Trading Symbol
TradingSymbol
AYTU
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10845591 shares
CY2016Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the Reverse Stock Splits). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.
CY2016Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
75466 USD
CY2016Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
589377 USD
CY2016Q3 aytu Compensation Through Issuance Of Stock
CompensationThroughIssuanceOfStock
509996 USD
CY2015Q3 aytu Compensation Through Issuance Of Stock
CompensationThroughIssuanceOfStock
0 USD
CY2016Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
589377 USD
CY2015Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
337525 USD
CY2015Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-10357 USD
CY2016Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-607881 USD
CY2015Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-121684 USD
CY2016Q3 aytu Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-668792 USD
CY2015Q3 aytu Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
420538 USD
CY2016Q3 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2015Q3 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
57637 USD
CY2015Q3 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0 USD
CY2016Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4721 USD
CY2015Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3554 USD
CY2016Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
24247 USD
CY2015Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2016Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2015Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5175000 USD
CY2016Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
631481 USD
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2016Q3 aytu Amortization Of Prepaid Research And Development Due To Related Parties
AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties
30496 USD
CY2015Q3 aytu Amortization Of Prepaid Research And Development Due To Related Parties
AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties
30496 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
698000 USD
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
466000 USD
CY2016Q3 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
0 USD
CY2015Q3 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
21000 USD
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y5M1D
CY2016Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1043713 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M29D
CY2016Q2 aytu Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price
ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice
6.19
CY2016Q3 aytu Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price
ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice
6.11
CY2016Q2 aytu Share Based Compensation Share Warrants Outstanding
ShareBasedCompensationShareWarrantsOutstanding
2201627 shares
CY2016Q3 aytu Share Based Compensation Share Warrants Outstanding
ShareBasedCompensationShareWarrantsOutstanding
2286545 shares
CY2016Q2 us-gaap Deferred Revenue
DeferredRevenue
426000 USD
CY2016Q3 us-gaap Contractual Obligation
ContractualObligation
15321000 USD
CY2016Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
10371000 USD
CY2016Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1345000 USD
CY2016Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1105000 USD
CY2016Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
2500000 USD
CY2016Q3 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
0 USD
CY2016Q3 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
USD
CY2016Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
607234 USD
CY2016Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
509996 USD
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M23D
CY2016Q3 aytu Share Based Compensation Share Warrants Issued As Part Of Settlement
ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement
84918 shares
CY2016Q3 aytu Share Based Compensation Share Warrants Issued As Part Of Settlement Weighted Average Exercise Price
ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice
4.00
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
75031 USD
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
437014 USD
CY2015Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57447 USD
CY2016Q3 aytu Fixed Assets Included In Accounts Payable
FixedAssetsIncludedInAccountsPayable
95866 USD
CY2015Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5200000 USD
CY2015Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
401000 USD
CY2015Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
103000 USD
CY2015Q3 aytu Placement Agents Cash Fee Percentage
PlacementAgentsCashFeePercentage
0.08 pure
CY2016Q3 aytu Placement Agents Cash Fee Percentage
PlacementAgentsCashFeePercentage
0.08 pure
CY2016Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
20000 USD
CY2016Q1 aytu Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
22254 shares
CY2016Q1 aytu Warrants Exercise Price Per Share
WarrantsExercisePricePerShare
7.80
CY2016Q2 aytu Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
22564 shares
CY2016Q2 aytu Warrants Exercise Price Per Share
WarrantsExercisePricePerShare
4.80
CY2016Q3 us-gaap Debt Instrument Convertible Terms Of Conversion Feature
DebtInstrumentConvertibleTermsOfConversionFeature
At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing it to 130% of shares calculated by dividing such note balance by $4.80,
CY2016Q2 aytu Warrants Exercisable Term
WarrantsExercisableTerm
P5Y
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
318000 USD
CY2016Q3 aytu Common Stock Option Repricing Program Description
CommonStockOptionRepricingProgramDescription
Board of Directors approved a common stock option repricing program whereby previously granted and unexercised options held by current employees, consultants and directors with exercise prices above $6.00 per share were repriced on a one-for-one basis to $3.23 per share
CY2016Q3 aytu Primsol Accretion Included In Accounts Payable
PrimsolAccretionIncludedInAccountsPayable
49126 USD
CY2015Q3 aytu Primsol Accretion Included In Accounts Payable
PrimsolAccretionIncludedInAccountsPayable
0 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4898748 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1188307 shares
CY2016Q3 us-gaap Investment Owned Unrecognized Unrealized Depreciation
InvestmentOwnedUnrecognizedUnrealizedDepreciation
0 USD
CY2016Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1043712 USD
CY2015Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
68322 USD
CY2016Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
75466 USD
CY2015Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
0 USD
CY2016Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
24247 USD
CY2016Q3 us-gaap Depreciation
Depreciation
19000 USD
CY2015Q3 us-gaap Depreciation
Depreciation
7000 USD
CY2016Q2 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
1041000 USD
CY2016Q3 us-gaap Investment Owned Unrecognized Unrealized Appreciation
InvestmentOwnedUnrecognizedUnrealizedAppreciation
728000 USD
CY2015Q3 aytu Fixed Assets Included In Accounts Payable
FixedAssetsIncludedInAccountsPayable
0 USD

Files In Submission

Name View Source Status
0001144204-16-132071-index-headers.html Edgar Link pending
0001144204-16-132071-index.html Edgar Link pending
0001144204-16-132071.txt Edgar Link pending
0001144204-16-132071-xbrl.zip Edgar Link pending
aytu-20160930.xml Edgar Link completed
aytu-20160930.xsd Edgar Link pending
aytu-20160930_cal.xml Edgar Link unprocessable
aytu-20160930_def.xml Edgar Link unprocessable
aytu-20160930_lab.xml Edgar Link unprocessable
aytu-20160930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v451002_10q.htm Edgar Link pending
v451002_ex31-1.htm Edgar Link pending
v451002_ex31-2.htm Edgar Link pending
v451002_ex32-1.htm Edgar Link pending